Login
$OGN
$13.90 +$0.00 (0.0%) After hours

$OGN 8-K SEC Filings

Filed On Filing
30 Oct 2026 8-K: Regulation FD Disclosure

This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended September 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in...

31 Jul 2026 8-K: Regulation FD Disclosure

This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended June 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu...

23 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders

A special meeting of stockholders (the “Special Meeting”) of Organon & Co., a Delaware corporation (the “Company”), was held on July 23, 2026 at 10:00 a.m., Eastern Time, via a virtual meeting website. The Special Meeting was held in ord...

17 Jul 2026 8-K: Other Events

As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Su...

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Apr 2026 8-K: Results of Operations and Financial Condition

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency.

27 Apr 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

Exhibit A Form of Certificate of Incorporation of the Surviving Corporation

20 Feb 2026 8-K: Other Events

As previously disclosed on February 12, 2026, the Audit Committee of the Board of Directors of Organon & Co. (the “Company”) conducted an independent review of the information brought to the Audit Committee’s attention on February 11, 20...

12 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency

10 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency

07 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

27 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

05 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt

12 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

27 May 2025 8-K: Other Events

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

01 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure

15 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

JERSEY CITY, N.J.-- (BUSINESS WIRE) -- April 15, 2025 -- Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at...

13 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency

21 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

23 Dec 2024 8-K: Other Events

On December 20, 2024, following the previously-announced resignation of Martha E. McGarry from the Board of Directors (the “Board”) of Organon & Co., the Board reduced its size to eleven members, which eliminated the vacancy created by M...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support